The first prospective trial for von Hippel-Lindau disease: pazopanib.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Follow-up report on pulmonary mucosa-associated lymphoma in a patient with von Hippel-Lindau disease.Journal of surgical case reports · 2024
   Article
2. Challenges and opportunities in rare cancer research in China.Science China. Life sciences · 2024
   Review
3. Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease.Journal of clinical medicine · 2020
   Article
4. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease.Scientific reports · 2019
   Article
5. Neuroendocrine neoplasms - think about it and choose the most appropriate diagnostic and therapeutic steps.Reviews in endocrine & metabolic disorders · 2018
   Article

Corrections and comments

• Comment on
  Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as